Finance

Lists
Why is CADL down 3.57%?
Dive Deeper
CADL:NASDAQ
Candel Therapeutics Inc
$5.13
-3.57%
(-0.19) 1D
$5.13
0.00% (0.00)
After hours
Closed: Nov 19, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CADL...
Open
$5.38
High
$5.45
Low
$5.07
Mkt. cap
402.43M
Avg. vol.
1.40M
Volume
1.16M
52-wk high
$14.00
52-wk low
$4.35
EPS
-$1.49
Beta
-0.27
Shares outstanding
78.45M
No. of employees
55
Open
$5.38
High
$5.45
Low
$5.07
Mkt. cap
402.43M
Avg. vol.
1.40M
Volume
1.16M
52-wk high
$14.00
52-wk low
$4.35
EPS
-$1.49
Beta
-0.27
Shares outstanding
78.45M
No. of employees
55
News stories
From web sources and news partners
About Candel Therapeutics Inc
CEO-
Employees55
Founded2003
HeadquartersNeedham, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 7 analysts giving stock ratings to CADL in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for CADL in the last 3 months.
Highest
Current $5.13
$25.00 (+387.33%)
Average
$17.29 (+237.04%)
Lowest
$11.00 (+114.42%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yigal Nochomovitz
Citi
Buy
Maintained
$20.00
+289.9%
11/16/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Maintained
$18.00
+250.9%
11/16/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Maintained
$11.00
+114.4%
11/13/2026
John Newman
Canaccord Genuity
Buy
Maintained
$13.00
+153.4%
11/13/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$15.00
+192.4%
11/13/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$19.00
+270.4%
11/13/2026
Maury Raycroft
Jefferies
Buy
Initiated
$25.00
+387.3%
10/22/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
$16.00
+211.9%
08/14/2026
Unknown Analyst
Cantor Fitzgerald
Buy
Initiated
$30.00
+484.8%
04/20/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10.82M
9.64M
19.59M
15.40M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.93M
6.64M
7.15M
7.59M
Operating expense
15.74M
16.28M
26.75M
22.98M
Total operating expenses
15.74M
16.28M
26.75M
22.98M
Operating income
-15.74M
-16.28M
-26.75M
-22.98M
Other non operating income
-13.43M
7.66M
-12.26M
883.00K
EBT including unusual items
-29.50M
-8.86M
-38.90M
-21.87M
EBT excluding unusual items
-29.49M
-8.86M
-38.90M
-21.87M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-29.50M
-8.86M
-38.90M
-21.87M
Net profit margin
-
-
-
-
Earnings per share
-0.29
-
-0.36
-0.27
Interest and investment income
1.10M
1.32M
1.67M
1.82M
Interest expense
-1.42M
-1.56M
-1.58M
-1.59M
Net interest expenses
-314.00K
-242.00K
97.00K
225.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-15.58M
-16.14M
-26.58M
-22.81M
Gain or loss from assets sale
-33.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps